Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis
Crossref DOI link: https://doi.org/10.1186/s40064-016-3404-x
Published Online: 2016-10-05
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Banerjee, S.
Gunda, P.
Drake, R. F.
Hamed, K. http://orcid.org/0000-0003-1896-9736
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (US)
License valid from 2016-10-05